Posts by Brian Westerlind
Consumer Label Comprehension
By Mary Borneman, Sr. Director of Communications & Public Affairs, Hyland’s, Inc. March 1, 2017 It’s not news that the Internet and access to information has created what one could…
Read MoreDisclosing Relationships with Influencers on Social Media
By Deborah Kelly, public relations manager, Boiron USA March 1, 2017 The core mission of the Federal Trade Commission (FTC) is to regulate advertising so businesses won’t mislead consumers or…
Read MoreOutlook 2017
By Mark Land, AAHP President March 1, 2017 2017 is shaping up to be a year in motion—both for our industry and our country. With a new Administration and Congress,…
Read MoreThe FTC and the Web
By Alvin J. Lorman, Association Counsel March 1, 2017 The recent claim by the Federal Trade Commission (FTC) that its policy statement on marketing of homeopathic drugs applies to labels…
Read MoreAAHP in 2016 and a Review of New Member Resources
Jan. 26, 2017 In 2016, the Education Committee produced four robust webinars, and industry leaders united at two membership meetings. As we step forward into 2017, it’s a good moment…
Read MoreThe Tale of the Contract Manufacturer: A Story Based on an AAHP Member Question
By Eric Foxman, AAHP Secretary Once upon a time, a special creature, the CIAMP (Company Interested in Alternative Medical Products), wanted Phoxman Farmaceuticals (PhoxFarm) to contract manufacture a product for…
Read MoreCongress to Tackle “Must Pass” FDA Legislation Next Year
The Prescription Drug User Fee Act (PDUFA) authorizes the Food and DrugAdministration (FDA) to collect fees from Rx pharmaceutical companies to help fund the agency’s drug review work, hire FDA…
Read MoreWhat About Your APIs and Q7 Requirements?
By Eric L. Foxman, R.Ph. Jan. 26, 2017 In September 2016, the U.S. Food and Drug Administration (FDA) issued a guidance document, entitled Q7 Good Manufacturing Practice Guidance for Active…
Read MoreThe European Pharmacopeia and How U.S. Manufacturers Can Use It
By Mark S. Phillips, Pharm. D. Jan. 26, 2017 On Jan. 1, 2017, the 9th edition of the European Pharmacopoeia (Ph. Eur.) became legally binding in its 37 European member…
Read MoreRegulatory Policy Analysis
A Tool for Evaluating the Regulatory Framework for Homeopathic Drug Products By Mark Land, AAHP President Today the combination of drug regulations, approval options, cost controls and societal health care…
Read More